Incannex Approved For Bioavailability Clinical Trial For Dronabinol-Based Drug For Treatment Of Obstructive Sleep Apnea
Portfolio Pulse from Vuk Zdinjak
Incannex Healthcare Limited (NASDAQ:IXHL) has received approval to commence a bioavailability/bioequivalence clinical trial on IHL-42X, its proprietary drug for treatment of obstructive sleep apnea. The trial will assess the pharmacokinetics and tolerability of the two active pharmaceutical ingredients in IHL-42X, dronabinol and acetazolamide. The trial will be conducted at CMAX Clinical Research in Adelaide, South Australia and managed by Novotech. The results will form a critical component of a future new drug application.
July 06, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incannex Healthcare has received approval to commence a clinical trial on its proprietary drug for treatment of obstructive sleep apnea. This could potentially accelerate the development of the drug product and reduce cost and timelines.
The approval for the clinical trial is a positive development for Incannex Healthcare as it could potentially accelerate the development of the drug product and reduce cost and timelines. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100